BridgeMD
Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i
EU CTIS ID: 2025-523374-17-01
What this study is testing
To determine by means of 18F-FDG PET/CT and 99mTc-Tetrofosmin SPECT whether myocardial IR affects cardiac function and coronary flow and is therefore a risk factor for cardiovascular events and diabetic cardiomyopathy in DM2 patients with myocardial IR phenotype
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- BMI around 30 kg/m2
- DM2
- no-smoking; no-alcohol
- HbA1c between 7-9%
You likely can't join if
- previous CVD events
- hepatic and kidney complications
- claustrophobia to PET/CT and SPECT
- treatment with SGLT2 inhibitors or GLP-1 analogs.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.